|
1
|
Quaas A, Rehkaemper J, Rueschoff J, Pamuk
A, Zander T, Hillmer A, Siemanowski J, Wittig J, Buettner R, Plum
P, et al: Occurrence of high microsatellite-instability/mismatch
repair deficiency in nearly 2,000 human adenocarcinomas of the
gastrointestinal tract, pancreas, and bile ducts: A study from a
large german comprehensive cancer center. Front Oncol.
11(569475)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhu J, Ma S, Xie S, Liu Z, Li Z and Wei W:
Biological correlates before esophageal cancer screening and after
diagnosis. Sci Rep. 11(17015)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Nakajima M and Kato H: Treatment options
for esophageal squamous cell carcinoma. Expert Opin Pharmacother.
14:1345–1354. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Tustumi F, Kimura MS, Takeda FR, Uema RH,
Salum RAA, Ribeiro-Junior U and Cecconello I: Prognostic factors
and survival analysis in esophageal carcinoma. Arq Bras Cir Dig.
29:138–141. 2016.PubMed/NCBI View Article : Google Scholar : (In English,
Portuguese).
|
|
7
|
Dai N, Ji F, Wright J, Minichiello L,
Sadreyev R and Avruch J: IGF2 mRNA binding protein-2 is a tumor
promoter that drives cancer proliferation through its client mRNAs
IGF2 and HMGA1. Elife. 6(e27155)2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ye S, Song W, Xu X, Zhao X and Yang L:
IGF2BP2 promotes colorectal cancer cell proliferation and survival
through interfering with RAF-1 degradation by miR-195. FEBS Lett.
590:1641–1650. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pu J, Wang J, Qin Z, Wang A, Zhang Y, Wu
X, Wu Y, Li W, Xu Z, Lu Y, et al: IGF2BP2 promotes liver cancer
growth through an m6A-FEN1-dependent mechanism. Front Oncol.
10(578816)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dahlem C, Barghash A, Puchas P, Haybaeck J
and Kessler SM: The insulin-like growth factor 2 mRNA binding
protein IMP2/IGF2BP2 is overexpressed and correlates with poor
survival in pancreatic cancer. Int J Mol Sci.
20(3204)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Janiszewska M, Suvà ML, Riggi N,
Houtkooper RH, Auwerx J, Clément-Schatlo V, Radovanovic I, Rheinbay
E, Provero P and Stamenkovic I: Imp2 controls oxidative
phosphorylation and is crucial for preserving glioblastoma cancer
stem cells. Genes Dev. 26:1926–1944. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Simon Y, Kessler SM, Bohle RM, Haybaeck J
and Kiemer AK: The insulin-like growth factor 2 (IGF2) mRNA-binding
protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC? Gut.
63:861–863. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
He X, Li W, Liang X, Zhu X, Zhang L, Huang
Y, Yu T, Li S and Chen Z: IGF2BP2 overexpression indicates poor
survival in patients with acute myelocytic leukemia. Cell Physiol
Biochem. 51:1945–1956. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cleynen I, Brants JR, Peeters K, Deckers
R, Debiec-Rychter M, Sciot R, Van de Ven WJ and Petit MM: HMGA2
regulates transcription of the Imp2 gene via an intronic regulatory
element in cooperation with nuclear factor-kappaB. Mol Cancer Res.
5:363–372. 2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Barghash A, Golob-Schwarzl N, Helms V,
Haybaeck J and Kessler SM: Elevated expression of the IGF2 mRNA
binding protein 2 (IGF2BP2/IMP2) is linked to short survival and
metastasis in esophageal adenocarcinoma. Oncotarget. 7:49743–49750.
2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li T, Hu PS, Lin JF, Ju HQ and Xu RH:
IDDF2019-ABS-0290 IGF2BP2 facilitates tumor progression via an
m6A-dependent mechanism in colorectal carcinoma. Gut. 68 (Suppl
1):A1–A166. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Albores-Saavedra J, Adsay NV and Crawford
JM: ‘Tumours of the gallbladder and extrahepatic bile ducts’, in
WHO Classification of Tumours of the Digestive System. Bosman FT,
Carneiro F, Hruban RH and Theise ND (eds). Lyon, France, IARC
Press, pp263-276, 2010.
|
|
18
|
Sobin LH and Compton CC: TNM seventh
edition: What's new, what's changed: Communication from the
international union against cancer and the American joint committee
on cancer. Cancer. 116:5336–5339. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Puschhof J, Post Y, Beumer J, Kerkkamp HM,
Bittenbinder M, Vonk FJ, Casewell NR, Richardson MK and Clevers H:
Derivation of snake venom gland organoids for in vitro venom
production. Nat Protoc. 16:1494–1510. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Detre S, Saclani Jotti G and Dowsett M: A
‘quickscore’ method for immunohistochemical semiquantitation:
Validation for oestrogen receptor in breast carcinomas. J Clin
Pathol. 48:876–878. 1995.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(T)(-Delta Delta C) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yang H, Xu L, Qian H, Niu X, Zhao D, Zhao
Z, Wu J, Liu L and Wang Y: Correlation between insulin-like growth
factor binding protein 3 and metastasis-associated gene 1 protein
in esophageal squamous cell carcinoma. Mol Med Rep. 13:4143–4150.
2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Alsop BR and Sharma P: Esophageal cancer.
Gastroenterol Clin North Am. 45:399–412. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Short MW, Burgers KG and Fry VT:
Esophageal cancer. Am Fam Physician. 95:22–28. 2017.PubMed/NCBI
|
|
25
|
Bell JL, Wächter K, Mühleck B, Pazaitis N,
Köhn M, Lederer M and Hüttelmaier S: Insulin-like growth factor 2
mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of
cancer progression? Cell Mol Life Sci. 70:2657–2675.
2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gu T, Horová E, Möllsten A, Seman NA,
Falhammar H, Prázný M, Brismar K and Gu HF: IGF2BP2 and IGF2
genetic effects in diabetes and diabetic nephropathy. J Diabetes
Complications. 26:393–398. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dai N, Zhao L, Wrighting D, Krämer D,
Majithia A, Wang Y, Cracan V, Borges-Rivera D, Mootha VK,
Nahrendorf M, et al: IGF2BP2/IMP2-deficient mice resist obesity
through enhanced translation of Ucp1 mRNA and other mRNAs encoding
mitochondrial proteins. Cell Metab. 21:609–621. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hou P, Meng S, Li M, Lin T, Chu S, Li Z,
Zheng J, Gu Y and Bai J: LINC00460/DHX9/IGF2BP2 complex promotes
colorectal cancer proliferation and metastasis by mediating HMGA1
mRNA stability depending on m6A modification. J Exp Clin Cancer
Res. 40(52)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Mu Q, Wang L, Yu F, Gao H, Lei T, Li P,
Liu P, Zheng X, Hu X, Chen Y, et al: Imp2 regulates GBM progression
by activating IGF2/PI3K/Akt pathway. Cancer Biol Ther. 16:623–633.
2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Lu M, Nakamura RM, Dent ED, Zhang JY,
Nielsen FC, Christiansen J, Chan EK and Tan EM: Aberrant expression
of fetal RNA-binding protein p62 in liver cancer and liver
cirrhosis. Am J Pathol. 159:945–953. 2001.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Liu X, Ye H, Li L, Li W, Zhang Y and Zhang
JY: Humoral autoimmune responses to insulin-like growth factor II
mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer. J
Immunol Res. 2014(326593)2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhang L, Liu Y, Hao S, Woda BA and Lu D:
IMP2 expression distinguishes endometrioid from serous endometrial
adenocarcinomas. Am J Surg Pathol. 35:868–872. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
McMullen ER, Gonzalez ME, Skala SL, Tran
M, Thomas D, Djomehri SI, Burman B, Kidwell KM and Kleer CG: CCN6
regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of
the breast. Breast Cancer Res Treat. 172:577–586. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cao J, Mu Q and Huang H: The roles of
insulin-like growth factor 2 mRNA-binding protein 2 in cancer and
cancer stem cells. Stem Cells Int. 2018(4217259)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wu X, Fan Y, Liu Y, Shen B, Lu H and Ma H:
Long non-coding RNA CCAT2 promotes the development of esophageal
squamous cell carcinoma by inhibiting miR-200b to upregulate the
IGF2BP2/TK1 axis. Front Oncol. 11(680642)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhou SL, Yue WB, Fan ZM, Du F, Liu BC, Li
B, Han XN, Ku JW, Zhao XK, Zhang P, et al: Autoantibody detection
to tumor-associated antigens of P53, IMP1, P16, cyclin B1, P62,
C-myc, Survivn, and Koc for the screening of high-risk subjects and
early detection of esophageal squamous cell carcinoma. Dis
Esophagus. 27:790–797. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Xu X, Yu Y, Zong K, Lv P and Gu Y:
Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic
cancer promotes cancer proliferation by activating the PI3K/Akt
signaling pathway. J Exp Clin Cancer Res. 38(497)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Boudoukha S, Cuvellier S and Polesskaya A:
Role of the RNA-binding protein IMP-2 in muscle cell motility. Mol
Cell Biol. 30:5710–5725. 2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN,
Chen ZH, Zeng ZL, Wang F, Zheng J, et al: METTL3 facilitates tumor
progression via an m6A-IGF2BP2-dependent mechanism in colorectal
carcinoma. Mol Cancer. 18(112)2019.PubMed/NCBI View Article : Google Scholar
|
